• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞戈非尼治疗晚期结直肠癌患者的长期生存：病例报告及文献综述

Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review.

作者信息

Brunetti Oronzo, Calabrese Angela, Palermo Loredana, Solimando Antonio Giovanni, Argentiero Antonella

机构信息

Medical Oncology Unit IRCCS Istituto Tumori "Giovanni Paolo II" Bari Italy.

Radiology Unit IRCCS Istituto Tumori "Giovanni Paolo II" Bari Italy.

出版信息

Clin Case Rep. 2019 Oct 24;7(12):2379-2383. doi: 10.1002/ccr3.2496. eCollection 2019 Dec.

DOI:10.1002/ccr3.2496
PMID:31893063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6935656/
Abstract

Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.

摘要

两项3期试验报告称，接受瑞戈非尼治疗的结直肠癌患者在三线治疗中生存期延长，最长治疗时间为16个月。在此，我们报告了一例对传统化疗难治的患者，该患者接受瑞戈非尼治疗后疾病长期稳定的独特病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee31/6935656/a2be79759f57/CCR3-7-2379-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee31/6935656/a2be79759f57/CCR3-7-2379-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee31/6935656/a2be79759f57/CCR3-7-2379-g001.jpg

相似文献

1
Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review.瑞戈非尼治疗晚期结直肠癌患者的长期生存：病例报告及文献综述
Clin Case Rep. 2019 Oct 24;7(12):2379-2383. doi: 10.1002/ccr3.2496. eCollection 2019 Dec.
2
Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.索凡替尼联合 PD-1 抑制剂信迪利单抗治疗微卫星稳定型难治性结直肠癌患者的长期生存：一例病例报告及文献复习。
BMC Gastroenterol. 2021 Oct 23;21(1):399. doi: 10.1186/s12876-021-01950-y.
3
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.regorafenib 在抗血管生成初治和化疗耐药的晚期结直肠癌患者中的疗效：一项 IIb 期试验的结果。
Oncologist. 2019 Sep;24(9):1180-1187. doi: 10.1634/theoncologist.2019-0067. Epub 2019 Jun 7.
4
Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.瑞戈非尼联合托瑞米芬在晚期结直肠癌三线及以上治疗中的疗效和安全性
J Oncol. 2021 Sep 24;2021:9959946. doi: 10.1155/2021/9959946. eCollection 2021.
5
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.阿特珠单抗联合或不联合 cobimetinib 对比regorafenib 治疗既往治疗的转移性结直肠癌（IMblaze370）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16.
6
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 联合最佳支持治疗对比安慰剂联合最佳支持治疗用于既往治疗的转移性结直肠癌亚洲患者（CONCUR）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.
7
Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?regorafenib 或重新挑战化疗：在转移性结直肠癌的三线治疗中哪种更有效？
Cancer Chemother Pharmacol. 2019 Jan;83(1):115-122. doi: 10.1007/s00280-018-3713-6. Epub 2018 Oct 29.
8
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.regorafenib 对比氟尿嘧啶替加氟/盐酸伊立替康在标准化疗失败的转移性结直肠癌患者中的倾向性评分分析（REGOTAS）：日本结直肠癌学会多中心观察性研究。
Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11.
9
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.regorafenib 治疗标准治疗后进展的转移性结直肠癌患者：大型、单臂、开放标签 IIIb 期 CONSIGN 研究结果。
Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.
10
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.regorafenib 单药治疗 RAS 突变型晚期结直肠癌（STREAM）患者的二线治疗：一项学术性、多中心、单臂、两阶段、二期研究。
ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3.

引用本文的文献

1
Pathological Characteristics, Prognostic Determinants and the Outcome of Patients Diagnosed with Colorectal Adenocarcinoma at the University Teaching Hospital of Kigali.基加利教学医院诊断为结直肠腺癌患者的病理特征、预后因素和结局。
Can J Gastroenterol Hepatol. 2022 Sep 20;2022:6608870. doi: 10.1155/2022/6608870. eCollection 2022.
2
COL11A1 is Downregulated by miR-339-5p and Promotes Colon Carcinoma Progression.COL11A1 受 miR-339-5p 下调并促进结肠癌进展。
Can J Gastroenterol Hepatol. 2022 May 28;2022:8116990. doi: 10.1155/2022/8116990. eCollection 2022.
3
Does Preoperative Waiting Time Affect the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients? A Retrospective Study from the West of China.

本文引用的文献

1
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.瑞戈非尼治疗非 V600E BRAF 突变型结直肠癌的长期疗效：一例报告。
BMC Cancer. 2019 Jun 11;19(1):567. doi: 10.1186/s12885-019-5763-5.
2
Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.瑞戈非尼对一名无KDR突变的转移性结直肠癌患者产生意外且持久的反应：一例病例报告。
Medicine (Baltimore). 2018 Jun;97(25):e11178. doi: 10.1097/MD.0000000000011178.
3
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.
术前等待时间是否会影响结直肠癌患者的短期预后？来自中国西部的回顾性研究。
Can J Gastroenterol Hepatol. 2022 Apr 30;2022:8235736. doi: 10.1155/2022/8235736. eCollection 2022.
4
Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis.可切除结直肠癌伴肺转移的遗传特征。
Can J Gastroenterol Hepatol. 2022 Apr 28;2022:2033876. doi: 10.1155/2022/2033876. eCollection 2022.
5
A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report.TGF-β 通路在转移性结直肠癌对瑞戈非尼反应中的潜在作用：一例报告。
Medicina (Kaunas). 2021 Nov 13;57(11):1241. doi: 10.3390/medicina57111241.
立体定向体部放射治疗在寡转移结直肠癌中的作用：一例接受瑞戈非尼治疗进展后长期缓解患者的临床病例报告
Medicine (Baltimore). 2017 Dec;96(48):e9023. doi: 10.1097/MD.0000000000009023.
4
Long-Term Survival with Regorafenib in -Mutated Metastatic Rectal Cancer.瑞戈非尼用于KRAS突变型转移性直肠癌的长期生存情况
Case Rep Oncol. 2017 Nov 20;10(3):1029-1034. doi: 10.1159/000484401. eCollection 2017 Sep-Dec.
5
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.难治性转移性直肠癌中瑞戈非尼超敏反应者的基因组分析：一例报告及文献综述
Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.
6
Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.对瑞戈非尼治疗反应良好达2年的转移性结直肠癌：一例报告
J Med Case Rep. 2017 Aug 18;11(1):227. doi: 10.1186/s13256-017-1366-4.
7
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.RAS/PIK3CA/BRAF肿瘤突变作为转移性结直肠癌患者一线贝伐单抗化疗反应预测指标的回顾性研究。
BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6.
8
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.总血管内皮生长因子及未与贝伐单抗结合的血管内皮生长因子作为结直肠癌中基于贝伐单抗化疗的潜在预测因素。
World J Gastroenterol. 2016 Jul 21;22(27):6287-95. doi: 10.3748/wjg.v22.i27.6287.
9
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.分子谱分析在结直肠癌治疗中的应用：聚焦瑞戈非尼
Onco Targets Ther. 2015 Oct 15;8:2949-57. doi: 10.2147/OTT.S79145. eCollection 2015.
10
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.分析循环DNA和蛋白质生物标志物以预测瑞戈非尼的临床活性并评估转移性结直肠癌患者的预后：CORRECT试验的回顾性探索性分析
Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.